[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100639502":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":30,"responsibleParty":46,"collaborators":20,"id":48,"slug":20,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":49,"sex":55,"minAge":56,"maxAge":20,"enrollmentInfo":57,"targetDuration":20,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":68,"overallStatus":74,"whyStopped":20,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"MRI-guided SBRT","EXPERIMENTAL","Patients with oligometastatic peritoneal carcinomatosis will receive MRI-guided stereotactic body radiotherapy (MRIgSBRT) delivered with a hybrid MRI-linear accelerator using online adaptive planning and real-time tumor tracking. Treatment dose will range from 30 to 50 Gy in 5 fractions according to clinical judgment and organ-at-risk constraints.",[13],"Device: MRI-guided stereotactic body radiotherapy",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DEVICE","MRI-guided stereotactic body radiotherapy","Patients will receive MRI-guided stereotactic body radiotherapy (MRIgSBRT) delivered using a hybrid MRI-linear accelerator with online adaptive planning and real-time tumor tracking. Treatment will consist of 30-50 Gy delivered in 5 fractions according to clinical judgment, target characteristics, and organ-at-risk constraints. Daily adaptive replanning may be performed to account for anatomical changes and optimize dose delivery in patients with oligometastatic peritoneal carcinomatosis.",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Luca Boldrini","PRINCIPAL_INVESTIGATOR",[26],{"name":23,"role":27,"phone":28,"phoneExt":20,"email":29},"CONTACT","+390630158195","luca.boldrini@policlinicogemelli.it",[31],{"facility":32,"status":20,"city":33,"state":20,"zip":34,"country":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"Gemelli ART (Advanced Radiation Therapy)-Fondazione Policlinico Universitario Agostino Gemelli IRCCS","Roma","000168","Italy",{"type":37,"coordinates":38},"Point",[39,40],11.10642,44.99364,{"lat":40,"lon":39},[43,45],{"name":23,"role":27,"phone":44,"phoneExt":20,"email":29},"+390630155701",{"name":23,"role":24,"phone":20,"phoneExt":20,"email":20},{"type":47,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100639502",false,"NCT07593261","MRI-Guided Adaptive Radiotherapy for Limited Peritoneal Metastases (MARACAS Trial).","MARACAS: A Phase II Trial of MRI-guided Adaptive Stereotactic RAdiotherapy in oligometastatiC Patients With Peritoneal Spread.","MARACAS","Inclusion Criteria:\n\n* Age ≥18 years\n* ECOG performance status 0-2\n* Life expectancy ≥6 months\n* Up to 5 MRI-visible peritoneal nodules\n* PCI ≤20\n* No prior radiotherapy in the same abdominal region within 6 months\n* Signed informed consent\n* History of prior CRS and\u002For HIPEC\n\nExclusion Criteria:\n\n* Diffuse peritoneal carcinomatosis\n* Psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule (those conditions should be discussed with the patient before registration in the trial)\n* Significant comorbidities (such as: severe cardiac or coagulative disease, moderate or severe\n* restrictive\u002Fobsiructive lung deficit, severe cognitive impairment, moderate and severe renal and hepatic impairment.\n* Pregnancy or breastfeeding\n* MRI contraindications (e.g., pacemaker, severe claustrophobia)","ALL","18 Years",{"count":58,"type":59},34,"ESTIMATED","INTERVENTIONAL",[62],"PHASE2","This prospective phase II study evaluates the efficacy and safety of MRI-guided stereotactic body radiotherapy (MRIgSBRT) in patients with oligometastatic peritoneal carcinomatosis from gastrointestinal or gynecological tumors. Eligible patients with up to 5 MRI-visible peritoneal lesions and PCI ≤20 will be treated with MRIgSBRT using a hybrid MRI-linear accelerator with online adaptive planning and real-time tumor tracking.\n\nThe primary endpoint is radiologic response rate according to RECIST 1.1 criteria. Secondary endpoints include overall survival, progression-free survival, local control, chemotherapy-free survival, and treatment-related toxicity. The study aims to assess MRIgSBRT as a safe and non-invasive treatment option for selected patients with limited peritoneal metastatic disease.",[65,66,67],"Peritoneal Carcinomatosis","Oligometastatic Disease","Peritoneal Metastases",[69,70,71,72,73],"MRI-guided radiotherapy","Stereotactic body radiotherapy","Peritoneal carcinomatosis","Peritoneal metastases","Online adaptive radiotherapy","NOT_YET_RECRUITING","2026-05-12",{"date":77,"type":78},"2026-05-18","ACTUAL",{"date":80,"type":59},"2026-07",{"date":82,"type":59},"2032-07",{"name":5,"class":6},1]